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In the past, many studies have documented the beneficial effects of deep brain stimulation
(DBS) in the globus pallidus internus for treatment of primary segmental or generalized dys-
tonia. Recently however, several reports focused on DBS-induced hypokinesia or freezing
of gait (FOG) as a side effect in these patients. Here we report on two patients suffering
from FOG after successful treatment of their dystonic movement disorder with pallidal high
frequency stimulation (HFS). Several attempts to reduce the FOG resulted in worsening of
the control of dystonia. In one patient levodopa treatment was initialized which was some-
what successful to relieve FOG. We discuss the possible mechanisms of hypokinetic side
effects of pallidal DBS which can be explained by the hypothesis of selective GABA release
as the mode of action of HFS. Pallidal HFS is also effective in treating idiopathic Parkinson’s
disease as a hypokinetic disorder which at first sight seems to be a paradox. In our view,
however, the GABAergic hypothesis can explain this and other clinical observations.
Keywords: deep brain stimulation, globus pallidus internus, subthalamic nucleus, idiopathic Parkinson’s disease,
dystonia
Deep brain stimulation (DBS) has become an established therapy
for treatment of distinct movement disorders. Since its introduc-
tion in 1987 on patients with tremor (1), this therapeutic interven-
tion has been used for a wide spectrum of diseases like idiopathic
Parkinson’s disease (IPD), tremor, dystonia, and recently epilepsy.
Moreover, studies and case series suggest efficacy in treatment of
distinct psychiatric diseases. However, high frequency stimulation
(HFS, i.e., stimulation above 100 Hz) of the internal globus pal-
lidus (GPi) has been shown to be highly effective in segmental
and generalized dystonia (2, 3), cervical dystonia (4, 5), and case
series of tardive dystonia (6–9). Surprisingly, in the latest years,
case reports and case series emerge, where pallidal HFS leads to
hypokinesia and freezing of gait (FOG) in these patients (10–13).
On the first sight this seems paradoxical, since pallidal HFS is also
applied to sufficiently treat patients with hypokinetic IPD (14, 15).
However, already in the first years of pallidal HFS for IPD, this con-
troversy has been described, admittedly leaving the reason for that
phenomenon unexplained (16).
So far, the mechanism of DBS is not known. Many hypotheses
based on in vitro or animal studies do exist, explaining functioning
of HFS/DBS via a “lesion effect” by reduced axonal output (17) or
pronounced inhibitory input; for a detailed review see Feuerstein
et al. (18) or McIntyre et al. (19). The GABAergic hypothesis (20)
is one out of these assumptions, which, especially in its form of
selective GABA release upon HFS (18), may explain the clinical
findings and characteristics of subthalamic and pallidal HFS in
IPD and dystonia, including their side effects.
This manuscript deals with the report of two patients who
underwent stereotactic neurosurgery for pallidal DBS as a
treatment for different types of dystonia. They both developed
severe FOG in parallel to effective treatment of the dystonic move-
ment disorder. We discuss these findings as supportive for the
GABA-selective hypothesis of HFS and provide an explanation
based on this hypothesis for the controversy mentioned above.
CASE 1
The first patient (caucasian female, 69 years) suffered from cervi-
cal dystonia with moderate torticollis to the right and laterocollis
to the left including dystonic head tremor since 8 years. Wilson’s
disease was ruled out by normal ceruloplasmin, serum-copper
levels, and liver values. Treatments covered botulinumtoxin, tri-
hexyphenidyl, tetrabenazine, and clonazepam without definite
relief of the dystonic symptoms. Due to an intractable neck
pain she developed reactive depression with sleep disturbances.
Prior to planned stereotactic neurosurgery for DBS we con-
ducted neuropsychological assessment which showed no cognitive
decline. Psychosomatic and psychiatric consultation confirmed
reactive depression, but represented no contraindication for oper-
ative treatment. DBS electrodes (DBS leads 3389; Medtronic Inc.,
Minneapolis, USA) were implanted in 04/2009 in local anesthe-
sia. Post-interventional computed tomography (CT) and fusion
with the preoperative magnet resonance imaging (MRI) showed
correct locations of both DBS electrodes in the GPi without
surgery-specific complications. The impulse generator (IPG) was
implanted 1 day later (Activa PC, Medtronic Inc., Minneapolis,
USA). The stimulation was introduced 3 days after implantation
with an immediate beneficial effect on neck pain and a mod-
erate effect for the dystonic movement including head tremor.
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Due to speech problems upon stimulation at the lowest contacts
that we interpret as an effect on the internal capsule, we changed
the stimulation parameters [contact 1/2(−) and 5/6(−) versus
IPG(+): 2.0 V, 90µs, 170 Hz]. Talairach stereotactic coordinates
for stimulation contact on the left are x =−20 mm, y = 4 mm, and
z =−4 mm, coordinates for stimulation contact on the right are
x = 21 mm, y = 2 mm, and z =−2 mm in relation to the point in
the middle of the line between the anterior and posterior commis-
sure (mid-AC-PC-point; obtained by post-interventional com-
puter tomography including stereotactic frame). FOG and limb
hypokinesia were first recognized in 08/2010 after further increase
of the stimulation parameters, accompanied by an optimal con-
trol of the head torsion (2.1 V, 150µs, 180 Hz). The patient’s gait
disturbances showed clear effects on levodopa therapy [UPDRS
motor score (off/on): 13/7]; regrettably, no further ranking scales
were applied at this time. We performed further investigations (FP-
CIT-SPECT and sonography of the midbrain) which revealed no
evidence of concomitant IPD. Furthermore, switch-off of the stim-
ulation or reduction of the stimulation amplitude dramatically
improved the patient’s gait, but induced certainly an increase of the
dystonic movements. Unfortunately, it was not possible to iden-
tify stimulation parameters (e.g., bipolar stimulation, interleaved
pulses, cyclic stimulation) with optimal control of the cervical
dystonia in the absence hypokinetic side effects. Increasing the
pulse width to heighten current density was also not helpful in
this patient. We also applied stimulation the dorsal contacts which
did not improve the FOG.
CASE 2
Our second patient (caucasian female, 63 years) suffered from a
progressive generalized dystonia since childhood. The sympto-
matology consisted of severe retrocollis, torticollis to the right,
opisthotonus of the spinal column and right accentuated limb
dystonia with head and limb tremor. Molecular genetic analy-
sis on DYT1 was negative, urine and serum probes for copper
homeostasis showed no evidence for Wilson’s disease. MRI-scan
revealed slight generalized brain atrophy. Tremor analysis of the
right and left upper limbs revealed irregular dystonic tremor with
a mean frequency of 4.6 and 3.5 Hz, respectively. Therapeutic
attempts included levodopa, cervical botulinumtoxin injections,
trihexyphenidyl, and baclofen, all without satisfactory effect. Thus,
we performed bilateral pallidal DBS in 08/2008 (Kinetra, DBS leads
3389; Medtronic Inc., Minneapolis, USA). Post-interventional CT
was merged with preoperative MRI and showed correct location
of both DBS electrodes in the GPi without surgery-specific com-
plications. During the course, the stimulation parameters were
adapted showing the best improvement on mainly the distorted
head, retrocollis, and tremor. Since monopolar stimulation lead to
severe left-accentuated FOG, a bipolar setting to narrow the elec-
trical field was chosen for the right GPi with the best compromise
between good effect on dystonia and moderate distracting effect
on gait [contact 1(−) versus IPG(+): 2.0 V, 240µs, 130 Hz; bipo-
lar setting contacts 5/6(−) versus 4/7(+): 2.3 V, 240µs, 130 Hz].
More dorsal contacts were tentatively used, but did not lower the
FOG. Talairach coordinates for stimulation contact on the left are
x =−20 mm, y = 6 mm, z =−1 mm, coordinates for stimulation
contact on the right are x = 21 mm, y = 5 mm, and z =−1 mm
in relation mid-AC-PC-point (obtained by post-interventional
computer tomography including stereotactic frame).
DISCUSSION
Two patients are presented here suffering from idiopathic dysto-
nia who were treated by pallidal DBS with a satisfactory effect
on the dystonic movement disorder. However, caused by HFS, a
hypokinetic disorder of the legs has becoming manifest as FOG.
This observation is cumulating in the past years, as patients with
pallidal HFS present with hypokinesia during writing or walking
(10–13). Levodopa responsiveness of these hypokinetic movement
disturbances has not been described so far, but in our first case,
the patient’s FOG improved after levodopa administration (see
UPDRS). In our second case we did not try levodopa for individual
reasons of the patient. Although the underlying pathophysiol-
ogy of FOG induced by pallidal HFS cannot be comprehensively
explained, we may suggest that it fits well into the GABA-selective
hypothesis of HFS functioning.
The GABAergic hypothesis was first introduced by Dostrovsky
et al. (20). In its form of HFS-induced selective GABA release
(18), it is based on the assumption, that only GABAergic axons,
but not other neuronal elements, respond to HFS and that the
evoked action potentials propagate ortho- and antidromically
along these axons. These action potentials only invade GABAergic
terminals, based on experimental findings that HFS of human
neocortical slices induces action potential-mediated exocytotic
release of GABA, but not of glutamate (18, 21). The hypothe-
sis of HFS-induced selective GABA release further proposes that
HFS operates via opening of GABAA autoreceptor-gated Cl−
channels of either terminal or somatodendritic location (18, 21).
Since the corresponding Cl− gradients in nerve endings favor
a depolarizing Cl− efflux (18, 21), terminal GABAA autorecep-
tors act in a facilitatory manner, thereby enhancing GABAergic
neurotransmission. Therefore, HFS of GABAergic axons leads to
an enhanced GABA release from GABAergic terminals, result-
ing in an increased postsynaptic inhibition of the downstream
nuclei.
The intention of the following discussion is to consider the
clinical findings in patients with dystonia and Parkinson’s dis-
ease particularly with regard to the above mentioned hypothe-
sis. It is not to review all arguments on that topic; for that we
refer to the reviews of McIntyre et al. (19) and Feuerstein et al.
(18). Our approach does not want to create the impression of
neglecting other findings and to use a mechanistic and simplis-
tic way to explain the mechanism of DBS or the basal ganglia
network. We rather assume that the constellation of unique HFS
parameters suggests a singular mechanism of action, correspond-
ing to the principle of optimal simplicity in explaining observed
effects.
In case of dystonia (Figure 1B), the GABAergic output of the
GPi to the thalamus seems to be reduced. The underlying patho-
physiology is not fully understood, but there is evidence for an
exaggerated direct pathway (striato-pallidal fibers) with enhanced
inhibition of the GPi. There also might be a reduced activity of
the indirect pathway with less excitation of the GPi by subthalamic
neurons [as reviewed in Hallett (22)]. Moreover, there is increasing
evidence for an involvement of cerebello-thalamo-cortical circuits
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FIGURE 1 | Schematic illustration (coronar view) of the proposed basal
ganglia network in a healthy condition (A) and in dystonia (B,C). In this
context it is not yet established, if for the direct pathways the striato-pallidal
efferents are overactive or if the indirect pathway (from Put to GPe) is
reduced. (B) depicts both possibilities resulting in a reduced inhibition of
the thalamus, leading to a hyperkinetic dystonic disorder. Following the
GABAergic hypothesis, pallidal HFS [(C), yellow circle] would result in a
normalized thalamic inhibition via increased GABAergic outflow and
therefore shows efficacy in reducing this hyperkinetic disorder (see also
Discussion). Thal, thalamus; STN, subthalamic nucleus; SNr/c, substantia
nigra pars reticularis/compacta; GPi/e, globus pallidus internus/externus;
Put, putamen; CN, caudate nucleus; Arrowheads (green for dopamine, red
for glutamate) reflect excitation; bars reflect inhibition (green for dopamine,
blue for GABA). Pyramidal tract: dark orange arrow=hyperkinetic
movement, light orange arrow= normokinetic movement.
as well as disynaptic interconnections between basal ganglia and
cerebellum in the pathophysiology of dystonia (23). Nevertheless,
the thalamus is disinhibited and its glutamatergic efferents to the
cortex provoke the hyperkinetic movement disorder. DBS for the
treatment of dystonic movement disorders is usually targeting the
ventro-medial parts of the GPi which contain the pallido-thalamic
fibers. Applying the GABA-selective hypothesis on this pathophys-
iological concept, HFS of these GABAergic pallido-fugal axons
would increase the GABAergic output onto the thalamus, resulting
in a suppression of the hyperkinetic movements (Figure 1C).
The somatotopic organization of the GPi reveals that neurons
in the ventro-lateral and posterior portion are responsible for the
upper extremity, whereas the representation of the lower limbs
lies more medio-dorsally and anteriorly within the GPi (24–27).
The area corresponding to the head and face is located medial
and ventral to the region of the upper extremity (24). Hypokinetic
side effects may occur when, depending on electrode localization,
pallidal HFS leads to an enhanced GABAergic output of both
the inhibited dystonic regions (e.g., in focal or segmental dys-
tonia) and the non-affected neurons of the GPi (Figures 2A,B).
Thus, the effect of HFS on the dystonic movement disorder may
be experienced satisfactorily even though it induces hypokinesia,
micrography, or FOG in many cases such as ours (Figure 2B).
This might also explain the clinical observation that hyperki-
netic movements such as dystonic tremor, dyskinesia, or kinetic
movements within a dystonic syndrome respond more intensely
to pallidal HFS than tonic movements, which correspond more
likely to hypokinetic movements. Furthermore, the hypokinetic
side effects of pallidal HFS are observations of the latest years,
when focal or segmental dystonia were more frequently treated
by implanted DBS electrodes. In generalized dystonia, however,
i.e., when the whole body is covered by the pathophysiology,
one would rarely expect these side effects. In our second patient,
the left lower limb was least affected by the generalized dysto-
nia, but, therefore, may have developed the greatest side effects
of FOG as a hypokinetic phenomenon. Furthermore, levodopa
was effective to treat FOG which was a side effect of pallidal
stimulation in the first patient. We explain this by a levodopa-
induced, D1 dopamine receptor-mediated rise in striato-pallidal
inhibition of the non-affected part of the GPi, which then can
be partly reversed, i.e., treated by the anti-hyperkinetic effect of
pallidal DBS.
On the contrary,HFS of the GPi is effective for treatment of IPD,
which is a typical hypokinetic disorder. Recently, a randomized-
controlled study showed good clinical responses for both subthal-
amic or pallidal DBS in IPD with lack of a statistical difference
between these groups (14). However, subthalamic stimulation
(STN-HFS) is often preferred and judged to be superior to pallidal
DBS, whereas the latter is frequently preserved for patients who
developed slight psychosis or mild dementia. Without doubt, pal-
lidal HFS is effective and increases quality of live in IPD patients,
but it should be considered that dopaminergic medication can-
not be significantly reduced after pallidal DBS as opposed to
STN-HFS.
The basal ganglia network in the parkinsonian hypokinetic
state is characterized by enhanced activity of the pallidal GABAer-
gic efferents resulting in pronounced inhibition of the thalamus
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FIGURE 2 | Differential efficacy of pallidal HFS depending on the
somatotopic distribution in focal/segmental dystonia (coronar view).
(A) Disinhibition of the thalamus in the upper extremity (neurons in the
ventro-lateral part of the GPi), but not in the lower limbs (medio-dorsal GPi),
resulting in dystonia of the arms but not the legs. HFS of the medial GPi
[(B), yellow circle] increases the GABAergic outflow of the pallido-fugal
fibers to the thalamus, which results in reduced hyperkinesia of the arms,
but in hypokinesia (e.g., FOG) of the legs. Abbreviations and symbols are as
in Figure 1. Pyramidal tract: dotted arrow=hypokinetic movement.
leading to hypokinesia (Figure 3A). Applying the GABA-selective
hypothesis of HFS functioning on this pathologic IPD basal gan-
glia network, HFS of the fiber tract in the medio-ventral part of the
GPi cannot further increase the GABAergic output to the thalamus
and, thus, does not provoke anti-hypokinetic effects here, since
the GABAergic transmission of the pallido-thalamic projection
is already maximal (Figure 3C). Else in STN-HFS (Figure 3E):
here an HFS-enhanced GABAergic input to the STN leads to a
more physiological state of the STN itself and of its downstream
nuclei. Moreover, pronounced STN-HFS even produces dyskine-
sia, as can be seen in some patients (28, 29). STN-HFS per se
therefore exhibits anti-hypokinetic and pro-hyperkinetic effects.
Thus, in a hyperkinetic state after levodopa medication, STN-
HFS is not effective in alleviating dyskinesia (Figure 3F) as it is
known from clinical practice. The reduction of dyskinesia upon
subthalamic HFS is mainly due to a reduction of the dopaminer-
gic medication. Nevertheless, we argue that the beneficial effect
of HFS in the ventro-medial parts of the GPi in IPD may be
founded on a symptomatic therapy of a hyperkinetic state owing
to dopaminergic medication (Figure 3B), since the dopaminer-
gic therapy often cannot be reduced after implantation. HFS of
pallido-fugal axons enhances GABA release in the thalamus and
thus causes an anti-hyperkinetic effect because of a normalized
thalamo-cortical projection (Figure 3D). The result is an over-
all increased “on-time” during daytime and a better quality of
life. However, producing a hyperkinetic state using an unchanged
or even exaggerated dopaminergic medication will cause stabi-
lization of the disorder due to the anti-hyperkinetic effect of
pallidal HFS. This was already seen in the early years of palli-
dal DBS for IPD (16), where HFS on different locations within
the GPi provoked distinct effects on bradykinesia and gait: stim-
ulation of the postero-ventro-medial part of the GPi was found
to worsen gait and bradykinesia (16), since pallidal HFS per se
is pro-hypokinetic (see Figure 3C), but was found to reduce
levodopa-induced dyskinesia by increasing GABA release in the
thalamus (which is anti-hyperkinetic, see Figure 3D). In turn, HFS
of the dorso-lateral part of the GPi was found to reduce hypoki-
nesia and rigidity in IPD as a symptomatic effect of pallidal HFS
(16). This also fits with the GABAergic hypothesis, since at this
stimulation site (blue circle in Figure 3C) the incoming GABAer-
gic fibers from the striatum are activated and thus enhance the
inhibition by released GABA of the pallidal GABAergic projec-
tion neurons. Hence, the inhibition of the GPi is increased by
HFS and, therefore, the thalamus gets disinhibited, resulting in
an anti-hypokinetic effect at this simulation site (blue circle in
Figure 3C).
The question arises why many dystonic patients do not have the
above mentioned problem of hypokinesia as a side effect of pal-
lidal stimulation. We suggest that this might be due to the above
mentioned somatotopic organization of the GPi. When the stimu-
lation is targeting mainly the somatotopic regions where dystonia
is prominent, one could have a beneficial effect on dystonia with-
out getting these side effects. Secondly, the number of patients
suffering from this phenomenon might be underestimated: there
are no systematic retrospective or even prospective evaluations
of dystonia patients regarding hypokinesia or the ability to walk.
We suppose that in a substantial portion of the patients with
focal or segmental dystonia this side effect occurs, but is small
in comparison to the benefit and therefore often neglected by the
patient.
In conclusion, we used the hypothesis of HFS-induced selective
GABA release to explain the hypokinetic side effects, i.e., FOG,
of pallidal HFS for treatment of dystonia and the sensitivity of
this side effect to levodopa treatment. Furthermore, this hypoth-
esis suits well to describe the clinical observation that in dystonia
hyperkinetic movements respond superiorly upon pallidal HFS in
comparison to the response of tonic movements. The GABAergic
theory beyond illustrates the mode of functioning of pallidal HFS
in IPD, which is in line with the clinical experiences. In addition,
the selective GABA release upon subthalamic HFS in IPD accounts
for its symptomatic efficacy.
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FIGURE 3 | Schematic model of the basal ganglia in IPD with and
without modulation by HFS (coronar view). Left column (A,C,E): basal
ganglia model of hypokinetic IPD. Right column (B,D,F): basal ganglia
model of the hyperkinetic state in IPD after years of levodopa treatment.
First row (A,B): basal ganglia model without DBS modulation. Second row
(C,D): modulation of the network by pallidal HFS (yellow circle). Third row
(E,F): modulation of the basal ganglia network by STN-HFS (yellow circle).
The GABAergic hypothesis illustrates why pallidal HFS is not effective in
the hypokinetic state of IPD (C), since the efferent GABAergic axons are
maximally recruited, whereas STN-HFS shows good efficacy (E).
(D) displays that in the hyperkinetic state (i.e., levodopa-induced
hyperkinesia) pallidal HFS is quite effective by producing an
anti-hyperkinetic effect via enhanced GABAergic outflow on the thalamus,
whereas STN-HFS per se is not effective to treat levodopa-induced
dyskinesia (F). The reason for this failure of STN-HFS is that the afferent
fibers to STN are already maximally active. Note, however, that STN-HFS
allows the reduction of the dosage of levodopa and thereby diminishes
hyperkinesia. Blue circle in (C) indicates stimulation of the striato-pallidal
fibers within the GPi as reconsidered in the discussion section.
Abbreviations and symbols are as in Figures 1 and 2.
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